Time | Risk factors | Cross tabulations | Resistance classes (odds ratio & 95% CI) | |||||
---|---|---|---|---|---|---|---|---|
TET | XNL+ | NAL+ | CIP + NAL + XNL+ | XNL+ | NAL+ | CIP + NAL + XNL+ | ||
Post | Enrofloxacin | |||||||
 Untreated | 70 | 42 | 21 | 22 |  |  |  | |
 Treated | 27 | 12 | 9 | 42 | 0.9 (0.4–2.2) | 0.8 (0.3–2.2) | 6.4 (2.4–16.9) | |
Sulfonamide | ||||||||
 Untreated | 25 | 9 | 4 | 2 |  |  |  | |
 Treated | 72 | 45 | 26 | 62 | 6.3 (1.9–20.5) | 0.7 (0.1–4.8) | 22.7 (4.0–127.3) | |
β-lactams | ||||||||
 Untreated | 43 | 23 | 5 | 13 |  |  |  | |
 Treated | 54 | 31 | 25 | 51 | 2.3 (0.8–6.0) | 4.8 (1.2–19.5) | 3.3 (1.1–9.8) | |
Age | ||||||||
 29 - 80d | 73 | 25 | 26 | 26 |  |  |  | |
 1 - 28d | 24 | 29 | 4 | 38 | 13.9 (4.5–43.3) | 0.9 (0.2–4.8) | 48.1 (14–165.3) | |
Transition | Enrofloxacin | |||||||
 Untreated | 46 | 32 | 38 | 34 |  |  |  | |
 Treated | 9 | 2 | 29 | 8 | 1.6 (0.3–9.7) | 4.4 (1.7–11.1) | 7.2 (1.7–30.1) | |
Sulfonamide | ||||||||
 Untreated | 1 | 13 | 0 | 5 |  |  |  | |
 Treated | 54 | 21 | 67 | 37 | 0.1 (0.01–1.2) | NA | 0.5 (0.05–5.2) | |
β-lactams | ||||||||
 Untreated | 22 | 23 | 19 | 19 |  |  |  | |
 Treated | 33 | 11 | 48 | 23 | 1.2 (0.4–3.8) | 1.2 (0.4–3.8) | 2.0 (0.6–4.7) | |
Age | ||||||||
 29 - 80d | 46 | 7 | 55 | 12 |  |  |  | |
 1 - 28d | 9 | 27 | 12 | 30 | 13.4 (3.7–49.1) | 2.2 (0.8–6.2) | 31.8 (8.4–120.3) |